CoChat
Sign Up
Cited by 32Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsAmyotrophic Lateral Sclerosis Research

Assessment of plasma and cerebrospinal fluid biomarkers in different stages of Alzheimer's disease and frontotemporal dementia

Open access
Álvarez-Sánchez, Lourdes, Peña-Bautista, Carmen, Ferré-González, Laura, Balaguer, Angel, Baquero, Miguel, Casanova-Estruch, Bonaventura, Cháfer-Pericás, Consuelo·2023·International Journal of Molecular Sciences
DOI 10.3390/ijms24021226PMC PMC9864037
Open this paper in CoChat — free accountOpen PDF

Abstract

Alzheimer’s disease (AD) is the primary type of dementia, followed by frontotemporal lobar degeneration (FTLD). They share some clinical characteristics, mainly at the early stages. So, the identification of early, specific, and minimally invasive biomarkers is required. In this study, some plasma biomarkers (Amyloid β42, p-Tau181, t-Tau, neurofilament light (NfL), TAR DNA-binding protein 43 (TDP-43)) were determined by single molecule array technology (SIMOA®) in control subjects (n = 22), mild cognitive impairment due to AD (MCI-AD, n = 33), mild dementia due to AD (n = 12), and FTLD (n = 11) patients. The correlations between plasma and cerebrospinal fluid (CSF) levels and the accuracy of plasma biomarkers for AD early diagnosis and discriminating from FTLD were analyzed. As result, plasma p-Tau181 and NfL levels correlated with the corresponding CSF levels. Additionally, plasma p-Tau181 showed good accuracy for distinguishing between the controls and AD, as well as discriminating between AD and FTLD. Moreover, plasma NfL could discriminate dementia-AD vs. controls, FTLD vs. controls, and MCI-AD vs. dementia-AD. Therefore, the determination of these biomarkers in plasma is potentially helpful in AD spectrum diagnosis, but also discriminating from FTLD. In addition, the accessibility of these potential early and specific biomarkers may be useful for AD screening protocols in the future.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms24021226

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Previous studies have evaluated protein correlations between plasma and CSF biomarkers of AD.

    “Previous studies have evaluated protein correlations between plasma and CSF biomarkers of AD. 37 , 38 , 39 , 40 , 41 , 42 , 43”

    From A genetic and proteomic comparison of key AD biomarkers across tissues (2024) · cites this paper as [38]

  • Previous studies found plasma NfL correlated relatively strongly with CSF NfL levels (r = 0.64-0.86; sample size 78-188).

    “including some that found plasma NfL correlated relatively strongly with CSF NfL levels (r = 0.64‐0.86; sample size 78‐188), 38 , 40 , 43”

    From A genetic and proteomic comparison of key AD biomarkers across tissues (2024) · cites this paper as [38]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 70

  1. [1]Snowden J.S. Neary D. Mann D.M.A. Frontotemporal Dementia Br. J. Psychiatry 2002 180 140 143 10.1192/bjp.180.2.140 11823324 · DOI
  2. [2]Ratnavalli E. Brayne C. Dawson K. Hodges J.R. The Prevalence of Frontotemporal Dementia Neurology 2002 58 1615 1621 10.1212/WNL.58.11.1615 12058088 · DOI
  3. [3]Blennow K. Zetterberg H. Biomarkers for Alzheimer’s Disease: Current Status and Prospects for the Future J. Intern. Med. 2018 284 643 663 10.1111/joim.12816 30051512 · DOI · Paper page
  4. [7]Hansson O. Zetterberg H. Vanmechelen E. Vanderstichele H. Andreasson U. Londos E. Wallin A. Minthon L. Blennow K. Evaluation of Plasma Abeta(40) and Abeta(42) as Predictors of Conversion to Alzheimer’s Disease in Patients with Mild Cognitive Impairment Neurobiol. Aging 2010 31 357 367 10.1016/j.neurobiolaging.2008.03.027 18486992 · DOI
  5. [8]Bjerke M. Engelborghs S. Cerebrospinal fluid biomarkers for early and differential Alzheimer’s disease diagnosis J. Alzheimers Dis. 2018 62 1199 1209 10.3233/JAD-170680 29562530 PMC5870045 · DOI
  6. [9]Tan C.-C. Yu J.-T. Tan L. Biomarkers for Preclinical Alzheimer’s Disease J. Alzheimers Dis. 2014 42 1051 1069 10.3233/JAD-140843 25024325 · DOI
  7. [10]Lewczuk P. Riederer P. O’Bryant S.E. Verbeek M.M. Dubois B. Visser P.J. Jellinger K.A. Engelborghs S. Ramirez A. Parnetti L. Cerebrospinal Fluid and Blood Biomarkers for Neurodegenerative Dementias: An Update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry World J. Biol. Psychiatry 2018 19 244 328 10.1080/15622975.2017.1375556 29076399 PMC5916324 · DOI
  8. [11]Ehrenberg A.J. Khatun A. Coomans E. Betts M.J. Capraro F. Thijssen E.H. Senkevich K. Bharucha T. Jafarpour M. Young P.N.E. Relevance of Biomarkers across Different Neurodegenerative Diseases Alzheimers Res. Ther. 2020 12 56 10.1186/s13195-020-00601-w 32404143 PMC7222479 · DOI
  9. [12]Chatterjee P. Elmi M. Goozee K. Shah T. Sohrabi H.R. Dias C.B. Pedrini S. Shen K. Asih P.R. Dave P. Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer’s Disease J. Alzheimers Dis. 2019 71 775 783 10.3233/JAD-190533 31424403 · DOI
  10. [14]Meyer D. Comparison of ELISA- and SIMOA-based quantification of plasma Aβ ratios for early detection of cerebral amyloidosis Alzheimer’s Res. Ther. 2020 12 162 10.1186/s13195-020-00728-w 33278904 PMC7719262 · DOI
  11. [15]Rembach A. Faux N.G. Watt A.D. Pertile K.K. Rumble R.L. Trounson B.O. Fowler C.J. Roberts B.R. Perez K.A. Li Q.-X. Changes in Plasma Amyloid Beta in a Longitudinal Study of Aging and Alzheimer’s Disease Alzheimers Dement. 2014 10 53 61 10.1016/j.jalz.2012.12.006 23491263 · DOI
  12. [16]Yamashita K. Miura M. Watanabe S. Ishiki K. Arimatsu Y. Kawahira J. Kubo T. Sasaki K. Arai T. Hagino K. Fully Automated and Highly Specific Plasma β-Amyloid Immunoassays Predict β-Amyloid Status Defined by Amyloid Positron Emission Tomography with High Accuracy Alzheimers Res. Ther. 2022 14 86 10.1186/s13195-022-01029-0 35739591 PMC9219197 · DOI
  13. [17]Janelidze S. Mattsson N. Palmqvist S. Smith R. Beach T.G. Serrano G.E. Chai X. Proctor N.K. Eichenlaub U. Zetterberg H. Plasma P-Tau181 in Alzheimer’s Disease: Relationship to Other Biomarkers, Differential Diagnosis, Neuropathology and Longitudinal Progression to Alzheimer’s Dementia Nat. Med. 2020 26 379 386 10.1038/s41591-020-0755-1 32123385 · DOI · Paper page
  14. [18]Hansson O. Cullen N. Zetterberg H. Blennow K. Mattsson-Carlgren N. the Alzheimer’s Disease Neuroimaging Initiative Plasma Phosphorylated Tau181 and Neurodegeneration in Alzheimer’s Disease Ann. Clin. Transl. Neurol. 2021 8 259 265 10.1002/acn3.51253 33249783 PMC7818141 · DOI
  15. [19]Tissot C. Therriault J. Kunach P. Comparing tau status determined via plasma pTau181, pTau231 and [18F] MK6240 tau-PET EBioMedicine 2022 76 103837 10.1016/j.ebiom.2022.103837 35134647 PMC8844756 · DOI
  16. [21]Doré V. Doecke J.D. Saad Z.S. Triana-Baltzer G. Slemmon R. Krishnadas N. Bourgeat P. Huang K. Burnham S. Fowler C. Plasma P217+tau versus NAV4694 Amyloid and MK6240 Tau PET across the Alzheimer’s Continuum Alzheimers Dement. 2022 14 e12307 10.1002/dad2.12307 PMC8984092 35415202 · DOI
  17. [22]Cho H.J. Schulz P. Venkataraman L. Caselli R.J. Sierks M.R. Sex-Specific Multiparameter Blood Test for the Early Diagnosis of Alzheimer’s Disease Int. J. Mol. Sci. 2022 23 15670 10.3390/ijms232415670 36555310 PMC9779188 · DOI
  18. [23]Cullen N.C. Leuzy A. Janelidze S. Palmqvist S. Svenningsson A.L. Stomrud E. Dage J.L. Mattsson-Carlgren N. Hansson O. Plasma Biomarkers of Alzheimer’s Disease Improve Prediction of Cognitive Decline in Cognitively Unimpaired Elderly Populations Nat. Commun. 2021 12 3555 10.1038/s41467-021-23746-0 34117234 PMC8196018 · DOI
  19. [24]Leuzy A. Mattsson-Carlgren N. Palmqvist S. Janelidze S. Dage J.L. Hansson O. Blood-based Biomarkers for Alzheimer’s Disease EMBO Mol. Med. 2022 14 e14408 10.15252/emmm.202114408 34859598 PMC8749476 · DOI
  20. [25]Janelidze S. Palmqvist S. Leuzy A. Stomrud E. Verberk I.M.W. Zetterberg H. Ashton N.J. Pesini P. Sarasa L. Allué J.A. Detecting Amyloid Positivity in Early Alzheimer’s Disease Using Combinations of Plasma Aβ42/Aβ40 and P-tau Alzheimers Dement. 2022 18 283 293 10.1002/alz.12395 34151519 · DOI · Paper page
  21. [27]Santangelo R. Agosta F. Masi F. Spinelli E.G. Cecchetti G. Caso F. Mandelli A. Cardamone R. Barbieri A. Furlan R. Plasma Neurofilament Light Chain Levels and Cognitive Testing as Predictors of Fast Progression in Alzheimer’s Disease Eur. J. Neurol. 2021 28 2980 2988 10.1111/ene.14999 34176186 · DOI
  22. [28]Li D. Zhang L. Nelson N.W. Mielke M.M. Yu F. Plasma Neurofilament Light and Future Declines in Cognition and Function in Alzheimer’s Disease in the FIT-AD Trial J. Alzheimers Dis. Rep. 2021 5 601 611 10.3233/ADR-210302 34514342 PMC8385429 · DOI
  23. [29]Pereira J.B. Janelidze S. Smith R. Mattsson-Carlgren N. Palmqvist S. Teunissen C.E. Zetterberg H. Stomrud E. Ashton N.J. Blennow K. Plasma GFAP Is an Early Marker of Amyloid-β but Not Tau Pathology in Alzheimer’s Disease Brain 2021 144 3505 3516 10.1093/brain/awab223 34259835 PMC8677538 · DOI · Paper page
  24. [30]Smirnov D.S. Ashton N.J. Blennow K. Zetterberg H. Simrén J. Lantero-Rodriguez J. Karikari T.K. Hiniker A. Rissman R.A. Salmon D.P. Plasma Biomarkers for Alzheimer’s Disease in Relation to Neuropathology and Cognitive Change Acta Neuropathol. 2022 143 487 503 10.1007/s00401-022-02408-5 35195758 PMC8960664 · DOI
  25. [31]Palmqvist S. Tideman P. Cullen N. Zetterberg H. Blennow K. Alzheimer’s Disease Neuroimaging Initiative Dage J.L. Stomrud E. Janelidze S. Mattsson-Carlgren N. Prediction of Future Alzheimer’s Disease Dementia Using Plasma Phospho-Tau Combined with Other Accessible Measures Nat. Med. 2021 27 1034 1042 10.1038/s41591-021-01348-z 34031605 · DOI · Paper page
  26. [32]Chatterjee P. Pedrini S. Ashton N.J. Tegg M. Goozee K. Singh A.K. Karikari T.K. Simrén J. Vanmechelen E. Armstrong N.J. Diagnostic and Prognostic Plasma Biomarkers for Preclinical Alzheimer’s Disease Alzheimers Dement. 2022 18 1141 1154 10.1002/alz.12447 34494715 · DOI · Paper page
  27. [33]Brickman A.M. Manly J.J. Honig L.S. Sanchez D. Reyes-Dumeyer D. Lantigua R.A. Lao P.J. Stern Y. Vonsattel J.P. Teich A.F. Plasma P-Tau181, p-Tau217, and Other Blood-Based Alzheimer’s Disease Biomarkers in a Multi-Ethnic, Community Study Alzheimers Dement. 2021 17 1353 1364 10.1002/alz.12301 33580742 PMC8451860 · DOI · Paper page
  28. [34]Elahi F.M. Casaletto K.B. La Joie R. Walters S.M. Harvey D. Wolf A. Edwards L. Rivera-Contreras W. Karydas A. Cobigo Y. Plasma Biomarkers of Astrocytic and Neuronal Dysfunction in Early- and Late-Onset Alzheimer’s Disease Alzheimers Dement. 2020 16 681 695 10.1016/j.jalz.2019.09.004 31879236 PMC7138729 · DOI
  29. [35]Qin Q. TREM2, microglia, and Alzheimer’s disease Mech. Ageing Dev. 2021 195 111438 10.1016/j.mad.2021.111438 33516818 · DOI · Paper page
  30. [36]Nelson P.T. Dickson D.W. Trojanowski J.Q. Jack C.R. Boyle P.A. Arfanakis K. Rademakers R. Alafuzoff I. Attems J. Brayne C. Limbic-Predominant Age-Related TDP-43 Encephalopathy (LATE): Consensus Working Group Report Brain 2019 142 1503 1527 10.1093/brain/awz099 31039256 PMC6536849 · DOI · Paper page
  31. [37]Meneses A. Koga S. O’Leary J. Dickson D.W. Bu G. Zhao N. TDP-43 Pathology in Alzheimer’s Disease Mol. Neurodegener. 2021 16 84 99 10.1186/s13024-021-00503-x 34930382 PMC8691026 · DOI
  32. [38]Robinson J.L. Richardson H. Xie S.X. Suh E. Van Deerlin V.M. Alfaro B. Loh N. Porras-Paniagua M. Nirschl J.J. Wolk D. The Development and Convergence of Co-Pathologies in Alzheimer’s Disease Brain 2021 144 953 962 10.1093/brain/awaa438 33449993 PMC8041349 · DOI · Paper page
  33. [39]Zetterberg H. Schott J.M. Blood Biomarkers for Alzheimer’s Disease and Related Disorders Acta Neurol. Scand. 2022 146 51 55 10.1111/ane.13628 35470421 · DOI
  34. [41]Das S. Dewit N. Jacobs D. Pijnenburg Y.A.L. In ’t Veld S.G.J.G. Coppens S. Quaglia M. Hirtz C. Teunissen C.E. Vanmechelen E. A Novel Neurofilament Light Chain ELISA Validated in Patients with Alzheimer’s Disease, Frontotemporal Dementia, and Subjective Cognitive Decline, and the Evaluation of Candidate Proteins for Immunoassay Calibration Int. J. Mol. Sci. 2022 23 7221 10.3390/ijms23137221 35806226 PMC9266977 · DOI · Paper page
  35. [42]Li Y. Schindler S.E. Bollinger J.G. Ovod V. Mawuenyega K.G. Weiner M.W. Shaw L.M. Masters C.L. Fowler C.J. Trojanowski J.Q. Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques Neurology 2022 98 e688 e699 10.1212/WNL.0000000000013211 34906975 PMC8865895 · DOI
  36. [43]Mielke M.M. Aakre J.A. Algeciras-Schimnich A. Proctor N.K. Machulda M.M. Eichenlaub U. Knopman D.S. Vemuri P. Graff-Radford J. Jack C.R. Jr. Comparison of CSF Phosphorylated Tau 181 and 217 for Cognitive Decline Alzheimers Dement. 2022 18 602 611 10.1002/alz.12415 34310832 PMC8789950 · DOI · Paper page
  37. [44]Mielke M.M. Hagen C.E. Xu J. Chai X. Vemuri P. Lowe V.J. Airey D.C. Knopman D.S. Roberts R.O. Machulda M.M. Plasma Phospho-Tau181 Increases with Alzheimer’s Disease Clinical Severity and Is Associated with Tau- and Amyloid-Positron Emission Tomography Alzheimers Dement. 2018 14 989 997 10.1016/j.jalz.2018.02.013 29626426 PMC6097897 · DOI · Paper page
  38. [45]Tatebe H. Kasai T. Ohmichi T. Kishi Y. Kakeya T. Waragai M. Kondo M. Allsop D. Tokuda T. Quantification of Plasma Phosphorylated Tau to Use as a Biomarker for Brain Alzheimer Pathology: Pilot Case-Control Studies Including Patients with Alzheimer’s Disease and down Syndrome Mol. Neurodegener. 2017 12 63 74 10.1186/s13024-017-0206-8 28866979 PMC5582385 · DOI
  39. [47]Moscoso A. Grothe M.J. Ashton N.J. Karikari T.K. Lantero Rodríguez J. Snellman A. Suárez-Calvet M. Blennow K. Zetterberg H. Schöll M. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain with Neurodegeneration in Alzheimer Disease JAMA Neurol. 2021 78 396 10.1001/jamaneurol.2020.4986 33427873 PMC7802009 · DOI
  40. [48]Müller S. Preische O. Göpfert J.C. Yañez V.A.C. Joos T.O. Boecker H. Düzel E. Falkai P. Priller J. Buerger K. Tau Plasma Levels in Subjective Cognitive Decline: Results from the DELCODE Study Sci. Rep. 2017 7 9529 10.1038/s41598-017-08779-0 28842559 PMC5573353 · DOI
  41. [49]Chouliaras L. Thomas A. Malpetti M. Donaghy P. Kane J. Mak E. Savulich G. Prats-Sedano M.A. Heslegrave A.J. Zetterberg H. Differential Levels of Plasma Biomarkers of Neurodegeneration in Lewy Body Dementia, Alzheimer’s Disease, Frontotemporal Dementia and Progressive Supranuclear Palsy J. Neurol. Neurosurg. Psychiatry 2022 93 651 658 10.1136/jnnp-2021-327788 35078917 PMC9148982 · DOI · Paper page
  42. [51]Toledo J.B. Vanderstichele H. Figurski M. Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI Acta Neuropathol. 2011 122 401 413 10.1007/s00401-011-0861-8 21805181 PMC3299300 · DOI
  43. [52]Hansson O. Stomrud E. Vanmechelen E. Östling S. Gustafson D.R. Zetterberg H. Blennow K. Skoog I. Evaluation of Plasma Aβ as Predictor of Alzheimer’s Disease in Older Individuals without Dementia: A Population-Based Study J. Alzheimers Dis. 2012 28 231 238 10.3233/JAD-2011-111418 21955816 · DOI
  44. [53]Pesaresi M. Lovati C. Bertora P. Mailland E. Galimberti D. Scarpini E. Quadri P. Forloni G. Mariani C. Plasma Levels of Beta-Amyloid (1-42) in Alzheimer’s Disease and Mild Cognitive Impairment Neurobiol. Aging 2006 27 904 905 10.1016/j.neurobiolaging.2006.03.004 16638622 · DOI
  45. [54]Chiu M.-J. Yang S.-Y. Chen T.-F. Lin C.-H. Yang F.-C. Chen W.-P. Zetterberg H. Blennow K. Synergistic Association between Plasma Aβ1–42 and p-Tau in Alzheimer’s Disease but Not in Parkinson’s Disease or Frontotemporal Dementia ACS Chem. Neurosci. 2021 12 1376 1383 10.1021/acschemneuro.1c00010 33825443 PMC9278807 · DOI
  46. [55]Lewczuk P. Ermann N. Andreasson U. Schultheis C. Podhorna J. Spitzer P. Maler J.M. Kornhuber J. Blennow K. Zetterberg H. Plasma Neurofilament Light as a Potential Biomarker of Neurodegeneration in Alzheimer’s Disease Alzheimers Res. Ther. 2018 10 71 10.1186/s13195-018-0404-9 30055655 PMC6064615 · DOI
  47. [56]Benedet A.L. Leuzy A. Pascoal T.A. Ashton N.J. Mathotaarachchi S. Savard M. Therriault J. Kang M.S. Chamoun M. Schöll M. Stage-Specific Links between Plasma Neurofilament Light and Imaging Biomarkers of Alzheimer’s Disease Brain 2020 143 3793 3804 10.1093/brain/awaa342 33210117 PMC7805809 · DOI
  48. [57]O’Bryant S. Petersen M. Hall J. Johnson L. Yaffe K. Braskie M. Toga A.W. Rissman R.A. HABLE study team Characterizing Plasma NfL in a Community-Dwelling Multi-Ethnic Cohort: Results from the HABLE Study Alzheimers Dement. 2022 18 240 250 10.1002/alz.12404 34310015 PMC9228481 · DOI
  49. [58]Corbet G.A. Wheeler J.R. Parker R. Weskamp K. TDP43 Ribonucleoprotein Granules: Physiologic Function to Pathologic Aggregates RNA Biol. 2021 18 (Suppl. 1) 128 138 10.1080/15476286.2021.1963099 34412568 PMC8677035 · DOI
  50. [59]Kuiperij H.B. Versleijen A.A.M. Beenes M. Verwey N.A. Benussi L. Paterlini A. Binetti G. Teunissen C.E. Raaphorst J. Schelhaas H.J. Tau rather than TDP-43 proteins are potential cerebrospinal fluid biomarkers for frontotemporal lobar degeneration subtypes: A pilot study J. Alzheimers Dis. 2016 55 585 595 10.3233/JAD-160386 27662293 · DOI
  51. [60]Foulds P. McAuley E. Gibbons L. Davidson Y. Pickering-Brown S.M. Neary D. Snowden J.S. Allsop D. Mann D.M.A. TDP-43 Protein in Plasma May Index TDP-43 Brain Pathology in Alzheimer’s Disease and Frontotemporal Lobar Degeneration Acta Neuropathol. 2008 116 141 146 10.1007/s00401-008-0389-8 18506455 PMC2464623 · DOI
  52. [61]Feneberg E. Gray E. Ansorge O. Talbot K. Turner M.R. Towards a TDP-43-Based Biomarker for ALS and FTLD Mol. Neurobiol. 2018 55 7789 7801 10.1007/s12035-018-0947-6 29460270 PMC6132775 · DOI
  53. [62]Hendricks R. Baker D. Brumm J. Davancaze T. Harp C. Herman A. von Büdingen H.-C. Townsend M. Fischer S.K. Establishment of Neurofilament Light Chain Simoa Assay in Cerebrospinal Fluid and Blood Bioanalysis 2019 11 1405 1418 10.4155/bio-2019-0163 31401845 · DOI
  54. [63]Aschenbrenner A.J. Li Y. Henson R.L. Volluz K. Hassenstab J. Verghese P. West T. Meyer M.R. Kirmess K.M. Fagan A.M. Comparison of Plasma and CSF Biomarkers in Predicting Cognitive Decline Ann. Clin. Transl. Neurol. 2022 9 1739 1751 10.1002/acn3.51670 36183195 PMC9639639 · DOI
  55. [64]Syrjanen J.A. Campbell M.R. Algeciras-Schimnich A. Vemuri P. Graff-Radford J. Machulda M.M. Bu G. Knopman D.S. Jack C.R. Jr. Petersen R.C. Associations of Amyloid and Neurodegeneration Plasma Biomarkers with Comorbidities Alzheimers Dement. 2022 18 1128 1140 10.1002/alz.12466 34569696 PMC8957642 · DOI
  56. [65]Gerards M. Schild A.-K. Meiberth D. Rostamzadeh A. Vehreschild J.J. Wingen-Heimann S. Johannis W. Martino Adami P. Onur O.A. Ramirez A. Alzheimer’s Disease Plasma Biomarkers Distinguish Clinical Diagnostic Groups in Memory Clinic Patients. Dement Geriatr. Cogn. Disord. 2022 51 182 192 10.1159/000524390 35504263 · DOI
  57. [66]Jiao B. Liu H. Guo L. Liao X. Zhou Y. Weng L. Xiao X. Zhou L. Wang X. Jiang Y. Performance of Plasma Amyloid β, Total Tau, and Neurofilament Light Chain in the Identification of Probable Alzheimer’s Disease in South China Front. Aging Neurosci. 2021 13 749649 10.3389/fnagi.2021.749649 34776933 PMC8579066 · DOI
  58. [67]Kokkinou M. Beishon L.C. Smailagic N. Noel-Storr A.H. Hyde C. Ukoumunne O. Worrall R.E. Hayen A. Desai M. Ashok A.H. Plasma and Cerebrospinal Fluid ABeta42 for the Differential Diagnosis of Alzheimer’s Disease Dementia in Participants Diagnosed with Any Dementia Subtype in a Specialist Care Setting Cochrane Database Syst. Rev. 2021 2 CD010945 10.1002/14651858.CD010945 33566374 PMC8078224 · DOI
  59. [68]Chiu P.-Y. Yang F.-C. Chiu M.-J. Lin W.-C. Lu C.-H. Yang S.-Y. Relevance of Plasma Biomarkers to Pathologies in Alzheimer’s Disease, Parkinson’s Disease and Frontotemporal Dementia Sci. Rep. 2022 12 17919 10.1038/s41598-022-22647-6 36289355 PMC9605966 · DOI
  60. [69]Benussi A. Cantoni V. Rivolta J. Archetti S. Micheli A. Ashton N. Zetterberg H. Blennow K. Borroni B. Classification Accuracy of Blood-Based and Neurophysiological Markers in the Differential Diagnosis of Alzheimer’s Disease and Frontotemporal Lobar Degeneration Alzheimers Res. Ther. 2022 14 155 10.1186/s13195-022-01094-5 36229847 PMC9558959 · DOI · Paper page
  61. [70]Huang H.-C. Tseng Y.-M. Chen Y.-C. Chen P.-Y. Chiu H.-Y. Diagnostic Accuracy of the Clinical Dementia Rating Scale for Detecting Mild Cognitive Impairment and Dementia: A Bivariate Meta-Analysis Int. J. Geriatr. Psychiatry 2021 36 239 251 10.1002/gps.5436 32955146 · DOI
  62. [71]Li Y. Xiong C. Aschenbrenner A.J. Chang C.-H. Weiner M.W. Nosheny R.L. Mungas D. Bateman R.J. Hassenstab J. Moulder K.L. Item Response Theory Analysis of the Clinical Dementia Rating Alzheimer Dement. 2021 17 534 542 10.1002/alz.12210 33215873 PMC8016711 · DOI
  63. [72]Tsoi K.K.F. Chan J.Y.C. Hirai H.W. Wong S.Y.S. Kwok T.C.Y. Cognitive Tests to Detect Dementia: A Systematic Review and Meta-Analysis: A Systematic Review and Meta-Analysis JAMA Intern. Med. 2015 175 1450 1458 10.1001/jamainternmed.2015.2152 26052687 · DOI
  64. [73]Mitchell A.J. A Meta-Analysis of the Accuracy of the Mini-Mental State Examination in the Detection of Dementia and Mild Cognitive Impairment J. Psychiatr. Res. 2009 43 411 431 10.1016/j.jpsychires.2008.04.014 18579155 · DOI
  65. [74]Encinas M. Gramunt-Fombuena S. Guia B. Hernanz C. Barbera A. Spanish translation and adaptation of the repeatable battery for the assessment of neuropsychological status (RBANS) Form A in a pilot sample Neurologia 2012 27 531 546 10.1016/j.nrl.2011.07.006 21906852 · DOI
  66. [75]Freilich B.M. Hyer L.A. Relation of the Repeatable Battery for Assessment of Neuropsychological Status to Measures of Daily Functioning in Dementia Psychol. Rep. 2007 101 119 129 10.2466/pr0.101.1.119-129 17958116 · DOI
  67. [76]Duff K. Humphreys Clark J.D. O’Bryant S.E. Mold J.W. Schiffer R.B. Sutker P.B. Utility of the RBANS in Detecting Cognitive Impairment Associated with Alzheimer’s Disease: Sensitivity, Specificity, and Positive and Negative Predictive Powers Arch. Clin. Neuropsychol. 2008 23 603 612 10.1016/j.acn.2008.06.004 18639437 PMC2570647 · DOI
  68. [77]Randolph C. Tierney M.C. Mohr E. Chase T.N. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Preliminary Clinical Validity J. Clin. Exp. Neuropsychol. 1998 20 310 319 10.1076/jcen.20.3.310.823 9845158 · DOI · Paper page
  69. [78]Rascovsky K. Hodges J.R. Knopman D. Mendez M.F. Kramer J.H. Neuhaus J. van Swieten J.C. Seelaar H. Dopper E.G.P. Onyike C.U. Sensitivity of Revised Diagnostic Criteria for the Behavioural Variant of Frontotemporal Dementia Brain 2011 134 Pt 9 2456 2477 10.1093/brain/awr179 21810890 PMC3170532 · DOI · Paper page
  70. [82]Kucheryavskiy S. mdatools—R package for chemometrics Chemom. Intell. Lab. Syst. 2020 198 103937 10.1016/j.chemolab.2020.103937 · DOI

Cited by

Sorted by citations

Authors
Álvarez-Sánchez, L., Peña-Bautista, C., Ferré-González, L., Balaguer, A., Baquero, M., Casanova-Estruch, B., & Cháfer-Pericás, C.
Affiliations
  • Alzheimer Disease Research Group, Instituto de Investigación Sanitaria La Fe, 46026 Valencia, Spain
  • Faculty of Mathematical Sciences, University of Valencia, 46100 Burjassot-Valencia, Spain
  • Hospital Universitari i Politècnic La Fe (ES)
ORCID
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2023-01-08
Volume
24
Issue
2
Pages
1226
ISSN
1422-0067 (ISSN-L)
DOI
10.3390/ijms24021226
PMC
PMC9864037
OpenAlex
W4313895196
Cited by
32
References
9
Citations by year
2026: 8 · 2025: 6 · 2024: 15 · 2023: 3
FWCI
6.49
Type
journal article
Language
en
Open access
Licence
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Instituto de Salud Carlos III (PI19/00570)
  • European Regional Development Fund (PI19/00570)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
Keywords
Alzheimer's disease, frontotemporal lobar degeneration, plasma biomarkers, cerebrospinal fluid biomarkers, phosphorylated tau 181, neurofilament light chain, amyloid-beta 42, total tau, TDP-43, mild cognitive impairment, early diagnosis, differential diagnosis, single molecule array
MeSH terms
Alzheimer Disease, Humans, Biomarkers, Amyloid beta-Peptides, tau Proteins, Pick Disease of the Brain, Frontotemporal Lobar Degeneration, Frontotemporal Dementia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review